Skip to main content
. 2019 Jun 25;140(4):270–279. doi: 10.1161/CIRCULATIONAHA.118.038814

Figure 1.

Figure 1.

MR estimates for the effect of genetically lower systolic blood pressure through the ACE inhibitor, β-blocker, and calcium channel blocker variants, respectively, on risk of coronary heart disease and stroke, compared with randomized, controlled trial meta-analysis results.3 ACE indicates angiotensin-converting enzyme; IVW, inverse variance weighted; and MR, Mendelian randomization.